Patents Examined by Jagadishwar R. Samala
  • Metal complexes and methods of treatment
    Patent number: 11266686
    Abstract: In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are NCDs of metal chelates, including complexes of iron, copper or zinc.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: March 8, 2022
    Inventors: John C. Warner, Srinivasa R. Cheruku, Anitha Hari, James J. Norman
  • Compounds for use as iron(III) MRI contrast agents
    Patent number: 11261208
    Abstract: Provided are macrocyclic compounds and compounds with two or more macrocyclic groups, iron coordinated macrocyclic compounds, and iron coordinated compounds with two or more macrocyclic groups. The iron is high-spin iron(III). The iron coordinated compounds may exhibit a negative redox potential (e.g., relative to a normal hydrogen electrode at a biologically relevant pH, for example, a pH of 6.5-7.5). The compounds can be used as MRI contrast agents.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: March 1, 2022
    Assignee: The Research Foundation for The State University of New York
    Inventors: Janet R. Morrow, Eric M. Snyder, Didar Asik
  • Bioorthogonal compositions
    Patent number: 11253600
    Abstract: Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of agents at the location of the tetrazine-containing biomaterial in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: February 22, 2022
    Assignees: TAMBO, INC., THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Jose Manuel Mejia Oneto, Nathan Yee, Maksim Royzen, Sangeetha Srinivasan, Ethan Miller
  • Systems and methods for preparing tailored radioactive isotope solutions
    Patent number: 11250965
    Abstract: The present disclosure relates to systems and methods for producing tailored solutions or medicaments containing radioactive isotopes (e.g., alpha particle emitting radioactive isotopes). The solutions may be produced by appropriate aging and separation steps. Therapeutically effective amounts of Ac-225 and/or Bi-213 may thus be obtained.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 15, 2022
    Assignee: RADTRAN LLC
    Inventor: Saleem S. Drera
  • Contrast agents for magnetic resonance imaging
    Patent number: 11235074
    Abstract: Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 1, 2022
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD
    Patent number: 11224668
    Abstract: The present invention provides compositions and methods for detecting GluA1, as a subunit protein and/or as a GluA1-containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluA1 expression or activity in a subject, which is a biological marker of PTSD.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: January 18, 2022
    Assignee: NEUROVATION LABS, INC.
    Inventor: Jennifer Perusini
  • Method for producing a fraction of Xenon radioisotopes, in particular Xe-133, fraction of Xenon radioisotopes, in particular Xe-133
    Patent number: 11227699
    Abstract: A method for producing a fraction of xenon radioisotopes, comprising the steps of dissolving enriched uranium targets forming a slurry and a gaseous phase containing xenon radioisotopes, isolating the xenon radioisotopes using zeolite doped with silver, preferably chosen from the group consisting of aluminosilicates doped with silver, titanosilicates doped with silver and mixtures thereof, and recovering the fraction of xenon radioisotopes, in particular Xe-133.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 18, 2022
    Assignee: Institut National Des Radioeléménts
    Inventors: Philippo Faga, Dominique Moyaux, Benoit Deconninck
  • Farnesoid X receptor agonists and uses thereof
    Patent number: 11214538
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 4, 2022
    Assignee: METACRINE, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek, Johnny Y. Nagasawa
  • SSTR-targeted conjugates and particles and formulations thereof
    Patent number: 11213590
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 4, 2022
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
  • Method and compositions for orally administered contrast agents for MR imaging
    Patent number: 11207429
    Abstract: Disclosed is CT or MR contrast agent which comprises a base or carrier scaffold formed of a polyhydroxol compound having a linker to which a Gd-DOTA is covalently bonded. Also disclosed is a method of screening a patient for colon cancer using a CT or MR contrast, which method comprises administering to a patient undergoing screening a compound as above described.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: December 28, 2021
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Eugene A. Mash, Parastou Foroutan, Suryakiran Navath, Robert J. Gillies, Gary V. Martinez, David L. Morse
  • Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
    Patent number: 11192903
    Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 7, 2021
    Assignee: The United States of Americans, as represented by the Secretary, Department of Health and Human Services
    Inventors: Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
  • Chemiluminescent probes for diagnostics and in vivo imaging
    Patent number: 11179482
    Abstract: The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: November 23, 2021
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Doron Shabat, Ronit Satchi-Fainaro, Nir Hananya, Ori Green, Tal Eilon
  • Diagnosis, treatment and prevention of neurotensin receptor-related conditions
    Patent number: 11180511
    Abstract: The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: November 23, 2021
    Assignee: Friedrich-Alexander-Universität Erlangen-Nürnberg; Universitätsklinikum Erlangen
    Inventors: Olaf Prante, Torsten Kuwert, Peter Gmeiner, Ashutosh Banerjee, Simone Maschauer
  • Tau PET imaging ligands
    Patent number: 11168068
    Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 9, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Guy Maurits R. Bormans, Lieven Denis Herwig Declercq, Katleen Fierens, Joseph Elisabeth Leenaerts, Diederik Willem Elisabeth Moechars, Frederik Jan Rita Rombouts, Hartmuth Kolb, Wei Zhang
  • Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
    Patent number: 11167049
    Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 9, 2021
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Shawn Hillier, John Joyal
  • Compositions and methods for assessing eye vasculature
    Patent number: 11160880
    Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: November 2, 2021
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Thomas E. Rogers
  • Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
    Patent number: 11161865
    Abstract: The present disclosure relates to compounds of Formula I and II, wherein R1-R20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 2, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert H. Mach, Sean Reilly, Mehran Makvandi, Kuiying Xu, Daniel A. Pryma, Roger A. Greenberg
  • Half-curcuminoids as amyloid-beta PET imaging agents
    Patent number: 11135318
    Abstract: Provided herein are curcumin analogues that are able to interact with amyloid beta (A?) and to attenuate the copper-induced crosslinking of A?. Also provided herein are methods of using the compounds as imaging agents of amyloid beta and for the treatment of diseases associated with amyloid beta. Methods of preparing unlabeled and radiolabeled compounds useful for interacting with amyloid beta and pharmaceutical compositions are also provided.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 5, 2021
    Assignee: The General Hospital Corporation
    Inventors: Chongzhao Ran, Anna Moore, Jian Yang
  • Radiopharmaceutical and methods
    Patent number: 11129912
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 28, 2021
    Assignee: POINT Biopharma Inc.
    Inventor: Joe McCann
  • Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
    Patent number: 11116782
    Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 14, 2021
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis